department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Jakafi · pharmadog

pharmadog
drugs
Jakafi

drug

patient view →

ruxolitinib

Marketedupdated 2mo ago

by Sun Pharmaceutical Industries Ltd

Approved

annual revenue · 2024–2024peak $2.8B

community read0 votes

all catalysts(1)

phase 3 initiation · 1

News(0)

no news has mentioned this drug yet

brand

Jakafi

generic

ruxolitinib

indication

myelofibrosis, polycythemia vera, graft-versus-host disease

phase

marketed

approved

2011-11-16

phase 3 initiation

Sun Pharmaceutical Industries Ltd — ruxolitinib (Phase III Trial Initiation)

Data sources

openFDA · ClinicalTrials.gov

last refreshed 14m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 2

companySun Pharmaceutical Industries Ltd1 co-mentions · 1 sources
tagDermatology1 co-mentions · 1 sources

Trials studying ruxolitinib

phase3Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areatarecruitingn=78
phase2Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansionactive not recruitingn=29
phase3A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitisactive not recruitingn=159
phase2Belumosudil With Ruxolitnib as Second Line Therapy for Chronic Graft Versus Host Disease (cGvHD) After Steroid Failurenot yet recruitingn=63
—Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Veraactive not recruitingn=242
phase1Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosisrecruitingn=6
phase2Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinibactive not recruitingn=305
phase1A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasmsrecruitingn=220

more trials →